Cargando…

Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival

We are witnessing a rapid worldwide increase in the incidence of papillary thyroid carcinoma (PTC) in the last thirty years. Extensive implementation of cancer screening and wide availability of neck ultrasound or other imaging studies is the main reason responsible for this phenomenon. It resulted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krajewska, Jolanta, Kukulska, Aleksandra, Oczko-Wojciechowska, Malgorzata, Kotecka-Blicharz, Agnieszka, Drosik-Rutowicz, Katarzyna, Haras-Gil, Malgorzata, Jarzab, Barbara, Handkiewicz-Junak, Daria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573306/ https://www.ncbi.nlm.nih.gov/pubmed/33123090 http://dx.doi.org/10.3389/fendo.2020.571421

Ejemplares similares

Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma—Do They Exist?
por: Szpak-Ulczok, Sylwia, et al.
Publicado: (2020)

Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma – Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015
por: Czarniecka, Agnieszka, et al.
Publicado: (2021)

TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2020)

The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAF(V600E) Mutation Status and Other Prognostic Factors
por: Czarniecka, Agnieszka, et al.
Publicado: (2015)

Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
por: Rusinek, Dagmara, et al.
Publicado: (2018)

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
por: Kukulska, Aleksandra, et al.
Publicado: (2010)

Gene signature of the post-Chernobyl papillary thyroid cancer
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2016)

A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping
por: Fujarewicz, Krzysztof, et al.
Publicado: (2007)

The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience
por: Krajewska, Jolanta, et al.
Publicado: (2013)

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
por: Kukulska, Aleksandra, et al.
Publicado: (2020)

Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma
por: Krajewska, Jolanta, et al.
Publicado: (2019)

Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer
por: Ledwon, Aleksandra, et al.
Publicado: (2021)

Current status of the prognostic molecular markers in medullary thyroid carcinoma
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2020)

Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
por: Rusinek, Dagmara, et al.
Publicado: (2017)

Novel TG‐FGFR1 and TRIM33‐NTRK1 transcript fusions in papillary thyroid carcinoma
por: Pfeifer, Aleksandra, et al.
Publicado: (2019)

13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2009)

Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours
por: Wojtas, Bartosz, et al.
Publicado: (2017)

Lobo-isthmectomy in the management of differentiated thyroid cancer
por: Krajewska, Jolanta, et al.
Publicado: (2023)

Transcriptional profiles of pilocytic astrocytoma are related to their three different locations, but not to radiological tumor features
por: Zakrzewski, Krzysztof, et al.
Publicado: (2015)

Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawal
por: Chechlinska, Magdalena, et al.
Publicado: (2009)

Molecular differential diagnosis of follicular thyroid carcinoma and adenoma based on gene expression profiling by using formalin-fixed paraffin-embedded tissues
por: Pfeifer, Aleksandra, et al.
Publicado: (2013)

Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells
por: Di Maro, Gennaro, et al.
Publicado: (2014)

Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Corrigendum: Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Analysis of the Role of FRMD5 in the Biology of Papillary Thyroid Carcinoma
por: Gaweł, Agata M., et al.
Publicado: (2021)

A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas
por: Dom, G, et al.
Publicado: (2012)

Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer
por: Kukulska, Aleksandra, et al.
Publicado: (2021)

Concentrations of Selected Adipokines, Interleukin-6, and Vitamin D in Patients with Papillary Thyroid Carcinoma in Respect to Thyroid Cancer Stages
por: Warakomski, Jakub, et al.
Publicado: (2018)

Estimation of groin recurrence risk in patients with squamous cell vulvar carcinoma by the assessment of marker gene expression in the lymph nodes
por: Kowalewska, Magdalena, et al.
Publicado: (2012)

Physician Perspectives of Overdiagnosis and Overtreatment of Low-Risk Papillary Thyroid Cancer in the US
por: Dedhia, Priya H., et al.
Publicado: (2022)

Overdiagnosis and overtreatment of breast cancer: Overdiagnosis and overtreatment in service screening
por: Paci, Eugenio, et al.
Publicado: (2005)

A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype–Phenotype Correlations
por: Soczomski, Przemysław, et al.
Publicado: (2021)

Factors Modifying Outcome After MIBG Therapy in Children With Neuroblastoma—A National Retrospective Study
por: Ussowicz, Marek, et al.
Publicado: (2021)

BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2015)

Overtreatment in the United States
por: Lyu, Heather, et al.
Publicado: (2017)

Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use of (1)H HR MAS NMR spectroscopy
por: Skorupa, Agnieszka, et al.
Publicado: (2021)

Intracranial Germinoma—Association between Delayed Diagnosis, Altered Clinical Manifestations, and Prognosis
por: Jabłońska, Iwona, et al.
Publicado: (2023)

Overtreatment of cruciate ligament injuries
por: Aspenberg, Per
Publicado: (2010)

Overtreatment of cruciate ligament injuries
por: Løken, Sverre, et al.
Publicado: (2011)

Overtreatment: Is a solution possible?
por: Hubbeling, Dieneke
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lnlbnp9vebp8dsr57145agcklp